New hope for elderly leukemia patients: drug combo shows promise

NCT ID NCT03466294

Completed Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, azacitidine and venetoclax, in 42 elderly patients (age 60+) with newly diagnosed acute myeloid leukemia (AML) who could not have standard chemotherapy. The treatment was given as an initial 'induction' phase, followed by a 'maintenance' phase with venetoclax alone for those who responded well. The goal was to see how long patients stayed in remission and how many achieved a deep response with no detectable cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and venetoclax
What this could lead to: If successful, this combination could offer a more effective, less toxic treatment option for elderly AML patients who cannot tolerate standard chemotherapy.
What could go wrong: This is a small, phase 2 study with only 42 participants. Results may not apply to all patients, and side effects like low blood counts or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

University of Colorado Denver

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.